Scientific deep-dive

Ozempic and Heart Rate: Why Semaglutide Raises Your Pulse (and What It Means) (2026)

A small rise in resting heart rate (about 1-4 bpm on average) is a labeled effect of semaglutide and the GLP-1 class. Why it happens, why SUSTAIN-6 and SELECT still showed reduced cardiovascular events, how to tell a normal pulse rise from palpitations, and the red flags worth reporting.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
8 min read·3 citations

A small rise in resting heart rate is a recognized, labeled effect of semaglutide and the wider GLP-1 receptor agonist class. On average it is modest — roughly one to four beats per minute — and for most people it is asymptomatic, something seen on a monitor rather than felt.[1] The reassuring part is the bigger picture: despite this small pulse bump, the large cardiovascular outcome trials for semaglutide — SUSTAIN-6 in people with type 2 diabetes and SELECT in people with obesity and established cardiovascular disease — found that semaglutide reduced major adverse cardiovascular events, so the net cardiovascular effect in at-risk patients was protective, not harmful.[2][3] What is worth separating from that average is a racing heart or palpitations as a symptom, which is a different thing and can instead point to dehydration, low blood sugar, anxiety, or an arrhythmia. This guide explains why the heart rate rises, why the outcome data still look favorable, when a fast or pounding pulse is a red flag, and what most people can do — usually nothing beyond awareness. Ozempic is semaglutide; see our Ozempic drug page and the broader Ozempic side effects guide for the full picture. This is general educational information, not medical advice — your prescriber manages your care.

About this article

The statement that semaglutide produces a small average increase in resting heart rate was checked against the FDA prescribing information on DailyMed (NIH) — the clinical-pharmacology and Adverse Reactions context of the Ozempic and Wegovy (semaglutide) labels — not an AI paraphrase or a third-party drug-monograph site.[1] The cardiovascular-outcome claims come from the two published pivotal trials themselves: SUSTAIN-6 (Marso and colleagues, New England Journal of Medicine, 2016) and SELECT (Lincoff and colleagues, New England Journal of Medicine, 2023).[2][3] The magnitude of the heart-rate rise varies by dose, by trial population, and by how it is measured, so treat the roughly one-to-four-beats-per-minute figure as an average, not a personal prediction. For the full side-effect profile see Ozempic side effects and the Ozempic drug page. This is general information, not medical advice — your prescriber individualizes your care.

Does Ozempic raise your heart rate?

Yes — modestly. A small increase in resting heart rate is a recognized, labeled effect of semaglutide and is described as a class effect across GLP-1 receptor agonists. Across studies the average rise lands in the range of roughly one to four beats per minute, and the semaglutide prescribing information reflects this small mean increase in heart rate in its clinical-pharmacology and adverse-reaction context.[1] The key word is average: a one-to-four-beat shift in a population mean is small, and for most individuals it is not something they notice. It does not, on its own, mean your heart is under strain.

Because Ozempic and Wegovy are the same molecule — semaglutide — the same mechanism applies across both products; the practical difference is dose. As with most semaglutide effects, the change is typically modest and asymptomatic, identified on a blood-pressure cuff or heart-rate monitor rather than felt as a symptom. That is an important framing for the rest of this guide, because the felt sensation of a racing or pounding heart — palpitations — is a separate issue we cover below, and it is not the same thing as the small average rise the label describes.[1]

Why semaglutide raises your pulse

The honest answer is that the exact mechanism is not fully settled. The leading explanation is that GLP-1 receptor agonists can mildly increase heart rate through autonomic effects — a small shift in the balance of sympathetic and parasympathetic input to the heart's natural pacemaker, the sinus node — nudging the resting rate upward. GLP-1 receptors are present in regions involved in cardiovascular and autonomic regulation, and the prevailing view is that the drug's action there produces the small chronotropic (heart-rate) effect rather than any direct toxic action on heart muscle.[1] Researchers have not pinned down a single definitive pathway, so this is best understood as a plausible, partly-characterized mechanism rather than a closed question.

It is also worth noting what the heart-rate rise is not. It is not the same as the palpitations some people feel, which usually have a different driver — dehydration, low blood sugar, anxiety, or an arrhythmia — covered in the next section. And it is not a marker of cardiovascular harm, which is where the outcome trials come in.

The counterpoint: semaglutide reduced cardiovascular events

Here is the part that reframes the whole question. Even with that small heart-rate rise, the large, randomized cardiovascular outcome trials of semaglutide found it reduced — not increased — major adverse cardiovascular events in at-risk patients. The net cardiovascular picture is protective, not harmful.

  • SUSTAIN-6 (Ozempic-dose semaglutide). In patients with type 2 diabetes at high cardiovascular risk, once-weekly semaglutide significantly lowered the rate of the composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke compared with placebo. This was the trial that established semaglutide's cardiovascular benefit in diabetes.[2]
  • SELECT (Wegovy-dose semaglutide, 2.4 mg). In adults aged 45 or older with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg was superior to placebo in reducing the same composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke over a mean follow-up of about 40 months.[3]

Taken together, these trials are why clinicians do not treat the small heart-rate increase as a reason to fear the drug's cardiovascular effect: in the populations studied, the on-balance result was fewer heart attacks, strokes, and cardiovascular deaths, not more. The modest pulse rise and the favorable outcome data coexist — a reminder that a single number on a monitor does not capture the full cardiovascular story.[2][3]

A small heart-rate rise vs palpitations as a symptom

It is important to separate the small average heart-rate rise — typically silent, seen on a monitor — from a racing, pounding, fluttering, or skipping heartbeat that you actually feel, which is what people mean by palpitations. The first is the labeled class effect described above. The second is a symptom, and it often has nothing to do with the small chronotropic effect and instead reflects a fixable driver:

  • Dehydration. The gastrointestinal side effects of semaglutide — nausea, vomiting, diarrhea — can cause fluid loss, and dehydration commonly speeds the heart and produces a pounding sensation, often with dizziness or lightheadedness on standing.[1]
  • Low blood sugar (hypoglycemia). Low glucose can cause a fast, pounding heartbeat alongside shakiness, sweating, and difficulty concentrating. The risk is higher when semaglutide is combined with insulin or a sulfonylurea.[1]
  • Anxiety. A racing heart is one of the most common physical features of anxiety and can be mistaken for a drug effect, particularly when someone is newly attentive to their heart.
  • An arrhythmia. Palpitations can occasionally signal an abnormal heart rhythm — for example atrial fibrillation — which is a separate medical issue that deserves evaluation rather than something to attribute to the drug by default.

The practical upshot: a felt racing or irregular heartbeat is worth reporting to your prescriber, because the most useful response is to look for the actual cause — hydration, glucose, anxiety, or rhythm — rather than to assume it is simply the expected average rise.

When a fast heart rate is a red flag

When to seek care

A small, symptom-free rise in resting heart rate is expected and usually needs no action. But seek prompt medical care for a persistently high resting heart rate, for palpitations accompanied by chest pain, shortness of breath, or fainting (or near-fainting), or for a very fast or irregular pulse — these are not the routine pattern and warrant urgent evaluation. If you have a known arrhythmia (such as atrial fibrillation) or take medications that affect heart rate or rhythm, tell your prescriber before and during treatment so your care can be individualized. Also treat and report a fast, pounding heartbeat that comes with shakiness, sweating, or confusion as possible low blood sugar, especially if you also use insulin or a sulfonylurea.[1] This box is general safety information, not a substitute for your clinician's judgment.

In short, the severity, the persistence, and the company a fast heartbeat keeps are what move it from "expected" to "get it checked." A pulse that is briefly a few beats faster and otherwise silent is the ordinary pattern; a sustained high rate, an irregular rhythm, or palpitations bundled with chest pain, breathlessness, or fainting are the signals that need attention.

What it means for you — and what to do

For most people the answer is reassuringly simple: no action is needed beyond awareness. The following are general, commonly-discussed points — all of them are prescriber-directed. Do not change your Ozempic dose, start supplements, or adjust other medications on your own.

  • Most people need do nothing. A small, asymptomatic rise in resting heart rate is an expected, labeled effect and is set against cardiovascular outcome data that, in at-risk patients, were favorable. It is not a reason to stop or fear the drug on its own.[1][3]
  • Monitor more closely if you have heart disease. If you have established cardiovascular disease, a known arrhythmia, or take rate- or rhythm-affecting medications, your prescriber may want to keep an eye on your heart rate and tailor the plan accordingly — so make sure they know your history.
  • Manage dehydration and low blood sugar. Because both can speed the heart, keep fluids and electrolytes steady (especially during any nausea, vomiting, or diarrhea), eat regular balanced meals, and follow your clinician's plan for treating lows — particularly if you use insulin or a sulfonylurea.[1]
  • Discuss it if you feel it. If you actually feel a racing, pounding, or irregular heartbeat — as opposed to merely reading a slightly higher number — tell your prescriber so the real cause (hydration, glucose, anxiety, or rhythm) can be sorted out.

For the full list of what is common versus serious, see Ozempic side effects, and for the basics of the medication itself see the Ozempic drug page. If you are choosing where to start or continue semaglutide under proper supervision, a legitimate provider reviews your cardiovascular history, titrates you on the label schedule, and follows up on effects like heart rate — exactly the monitoring that keeps treatment safe.

Frequently Asked Questions

Yes, but only modestly. A small increase in resting heart rate is a recognized, labeled effect of semaglutide and the GLP-1 receptor agonist class. On average the rise is roughly one to four beats per minute, and for most people it is asymptomatic — something seen on a monitor rather than felt. Because Ozempic and Wegovy are the same molecule, the same effect applies across both, with dose being the main difference. The change is generally too small to notice and, on its own, does not mean your heart is under strain.
The exact mechanism is not fully settled. The leading explanation is that GLP-1 receptor agonists can mildly increase heart rate through autonomic effects — a small shift in the sympathetic and parasympathetic input to the heart's natural pacemaker, the sinus node — that nudges the resting rate upward. It is a partly-characterized class effect rather than a fully proven single pathway, and it reflects the drug's action on cardiovascular and autonomic regulation, not any direct toxic effect on heart muscle.
Generally no, in the context of the outcome data. Despite the small heart-rate increase, the large cardiovascular outcome trials of semaglutide found it reduced rather than increased major adverse cardiovascular events in at-risk patients: SUSTAIN-6 in people with type 2 diabetes and SELECT in people with obesity and established cardiovascular disease both showed fewer cardiovascular deaths, heart attacks, and strokes versus placebo. So the net cardiovascular picture in those populations is protective, not harmful. The modest pulse rise and the favorable outcomes coexist.
The small average heart-rate rise is the labeled class effect — usually silent and detected on a monitor. Palpitations are a felt symptom: a racing, pounding, fluttering, or skipping heartbeat. The two are not the same. Palpitations often have a separate, fixable driver such as dehydration from gastrointestinal side effects, low blood sugar (more likely if you also take insulin or a sulfonylurea), anxiety, or occasionally an arrhythmia. A felt racing or irregular heartbeat is worth reporting to your prescriber so the actual cause can be identified.
The jittery or pounding feeling most people notice on semaglutide is usually not the small average heart-rate rise described in the label - that one-to-four-beat shift is typically silent and felt by very few people. Jitteriness and palpitations more often trace to one of four fixable drivers: dehydration from nausea or vomiting (which reduces blood volume and speeds the heart), low blood sugar if you also take insulin or a sulfonylurea (shakiness, sweating, and a pounding heart are classic hypoglycemia signs), anxiety triggered by nausea or the physical changes of early treatment, or an underlying heart-rhythm issue that was already present. Eating irregularly or skipping meals while appetite is suppressed can also cause blood-sugar swings that produce a jittery or shaky feeling even without frank hypoglycemia, so regular protein-forward meals help. Tell your prescriber if the sensation persists, comes with chest pain or breathlessness, or if you use insulin or a sulfonylurea, so the actual cause can be identified and addressed.
Seek prompt care for a persistently high resting heart rate, for palpitations accompanied by chest pain, shortness of breath, or fainting or near-fainting, or for a very fast or irregular pulse — these are not the routine pattern and warrant urgent evaluation. Also treat and report a fast, pounding heartbeat with shakiness, sweating, or confusion as possible low blood sugar, especially if you use insulin or a sulfonylurea. If you have a known arrhythmia or take medications that affect heart rate or rhythm, tell your prescriber so your care can be individualized.
For most people, no — a small, symptom-free rise needs no action and sits alongside cardiovascular outcome data that, in at-risk patients, were favorable. Monitor more closely if you have heart disease, a known arrhythmia, or take rate- or rhythm-affecting medications, and make sure your prescriber knows your history. Manage dehydration and low blood sugar, since both can speed the heart, by keeping fluids and electrolytes steady and eating regular meals. And if you actually feel a racing or irregular heartbeat, discuss it with your prescriber. Do not change your dose or other medications on your own.

References

  1. 1.Novo Nordisk Inc. OZEMPIC (semaglutide) injection, for subcutaneous use — US Prescribing Information: small mean increase in resting heart rate in clinical-pharmacology and Adverse Reactions context, plus hypoglycemia with insulin or a sulfonylurea and dehydration from gastrointestinal adverse reactions. DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. 2.Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6): once-weekly semaglutide reduced the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke versus placebo. N Engl J Med. 2016. https://pubmed.ncbi.nlm.nih.gov/27633186/
  3. 3.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT): semaglutide 2.4 mg was superior to placebo in reducing cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with cardiovascular disease and overweight or obesity but no diabetes. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/

Mounjaro and Heart Rate: Why Tirzepatide Raises Your Pulse (and What It Means) (2026)

A small rise in resting heart rate (roughly 2-5 bpm) is a labeled effect of tirzepatide (Mounjaro). Why it happens, the key evidence nuance vs semaglutide — tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing — how to tell a modest pulse rise from palpitations, and the red flags.

8 min read

Zone 2 Cardio for Weight Loss: What the Evidence Actually Shows

What zone 2 cardio actually is physiologically, how to estimate your zone 2 heart rate, the real evidence for its fat-oxidation and cardio benefits, and why it fits a GLP-1 routine.

9 min read

Does a GLP-1 Affect Blood Pressure? Lower, Higher, or Both — The Evidence

A thousand patients a month search 'does semaglutide lower blood pressure' or 'can semaglutide cause high blood pressure.' The honest answer is: GLP-1s lower systolic blood pressure by about 5-7 mmHg on average via weight loss and direct vascular mechanisms, with a small subset of patients experiencing dose-dependent heart-rate increases. Here is the evidence from STEP-1, SURMOUNT-1, SELECT, and the antihypertensive interaction.

11 min read

Mounjaro and Blood Pressure: Does Tirzepatide Lower It? (2026)

Mounjaro (tirzepatide) tends to modestly lower blood pressure, not raise it — a dose-related, weight-loss-driven drop confirmed by the SURMOUNT-1 24-hour ambulatory blood pressure substudy. Why it's usually a benefit, when it can overshoot into low blood pressure, and how to monitor it safely.

8 min read

GLP-1 and HFrEF Heart Failure: The Evidence (2026)

GLP-1 drugs help in HFpEF, but the randomized HFrEF trials (FIGHT, LIVE) of liraglutide showed no benefit, a faster heart rate, and possible harm signals.

12 min read

SELECT Trial: Beyond MACE - Secondary Endpoints (2026)

SELECT's prespecified secondary analyses: semaglutide cut a kidney composite 22%, helped heart failure across HFpEF and HFrEF, and held 10.2% weight loss 4 years.

13 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.8

Yucca Health

Mainstream telehealth GLP-1 access

7.7

TrimRx

Best overall value

7.6

Sprout Health

LegitScript-verified compounded GLP-1 via named pharmacies